Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence

N. Biglia, V. E. Bounous, M. Gallo, L. Fuso, L. G. Sgro, F. Maggiorotto, R. Ponzone

Research output: Contribution to journalArticle

Abstract

Objectives: To investigate the role and feasibility of sentinel lymph node biopsy (SLNB) in breast cancer patients with a local recurrence and no clinically positive axillary lymph nodes. Materials and Methods: A total of 71 patients underwent SLNB for breast cancer recurrence. At first surgery, they had received SLNB (46.5%), axillary lymph node dissection (ALND) (36.6%) or no axillary surgery (16.9%). Results: Lymphatic migration was successful in 53 out of 71 patients (74.6%) and was significantly higher in patients with previous SLNB or no axillary surgery than in those with previous ALND (87.9% vs. 53.8%; p = 0.009). Aberrant lymphatic migration pathways were observed in 7 patients (13.2%). The surgical SLNB was successfully performed in 51 patients (71.8%). In 46 patients (90.2%) the SLN was histologically negative, in 3 patients (5.9%) micrometastastatic and in 2 patients (3.9%) macrometastatic. The 2 patients with a macrometastates in SLN underwent ALND, In 4 out of the 18 patients with failure of tracer migration ALND, performed as surgeon's choice, did not find any metastatic node. After a median follow-up period of 39 months (range: 2–182 months), no axillary recurrence has been diagnosed. Conclusion: A SLNB in patients with locally recurrent breast cancer, no previous ALND and negative axillary lymph nodes is technically feasible and impacts on the ALND rate. In patients who at primary surgery received ALND, migration rate is significantly lower, aberrant migration is frequent and no clinically useful information has been obtained.

Original languageEnglish
Pages (from-to)8-13
Number of pages6
JournalBreast
Volume41
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Breast Neoplasms
Biopsy
Safety
Recurrence
Sentinel Lymph Node Biopsy
Lymph Node Excision
cyhalothrin
Lymph Nodes

Keywords

  • Aberrant lymphatic migration
  • Breast cancer
  • Migration rate
  • Outcome
  • Recurrence
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence. / Biglia, N.; Bounous, V. E.; Gallo, M.; Fuso, L.; Sgro, L. G.; Maggiorotto, F.; Ponzone, R.

In: Breast, Vol. 41, 01.10.2018, p. 8-13.

Research output: Contribution to journalArticle

Biglia, N. ; Bounous, V. E. ; Gallo, M. ; Fuso, L. ; Sgro, L. G. ; Maggiorotto, F. ; Ponzone, R. / Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence. In: Breast. 2018 ; Vol. 41. pp. 8-13.
@article{9162f49a8cc743f5bdc450c10cd8ee53,
title = "Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence",
abstract = "Objectives: To investigate the role and feasibility of sentinel lymph node biopsy (SLNB) in breast cancer patients with a local recurrence and no clinically positive axillary lymph nodes. Materials and Methods: A total of 71 patients underwent SLNB for breast cancer recurrence. At first surgery, they had received SLNB (46.5{\%}), axillary lymph node dissection (ALND) (36.6{\%}) or no axillary surgery (16.9{\%}). Results: Lymphatic migration was successful in 53 out of 71 patients (74.6{\%}) and was significantly higher in patients with previous SLNB or no axillary surgery than in those with previous ALND (87.9{\%} vs. 53.8{\%}; p = 0.009). Aberrant lymphatic migration pathways were observed in 7 patients (13.2{\%}). The surgical SLNB was successfully performed in 51 patients (71.8{\%}). In 46 patients (90.2{\%}) the SLN was histologically negative, in 3 patients (5.9{\%}) micrometastastatic and in 2 patients (3.9{\%}) macrometastatic. The 2 patients with a macrometastates in SLN underwent ALND, In 4 out of the 18 patients with failure of tracer migration ALND, performed as surgeon's choice, did not find any metastatic node. After a median follow-up period of 39 months (range: 2–182 months), no axillary recurrence has been diagnosed. Conclusion: A SLNB in patients with locally recurrent breast cancer, no previous ALND and negative axillary lymph nodes is technically feasible and impacts on the ALND rate. In patients who at primary surgery received ALND, migration rate is significantly lower, aberrant migration is frequent and no clinically useful information has been obtained.",
keywords = "Aberrant lymphatic migration, Breast cancer, Migration rate, Outcome, Recurrence, Sentinel lymph node biopsy",
author = "N. Biglia and Bounous, {V. E.} and M. Gallo and L. Fuso and Sgro, {L. G.} and F. Maggiorotto and R. Ponzone",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.breast.2018.06.004",
language = "English",
volume = "41",
pages = "8--13",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence

AU - Biglia, N.

AU - Bounous, V. E.

AU - Gallo, M.

AU - Fuso, L.

AU - Sgro, L. G.

AU - Maggiorotto, F.

AU - Ponzone, R.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Objectives: To investigate the role and feasibility of sentinel lymph node biopsy (SLNB) in breast cancer patients with a local recurrence and no clinically positive axillary lymph nodes. Materials and Methods: A total of 71 patients underwent SLNB for breast cancer recurrence. At first surgery, they had received SLNB (46.5%), axillary lymph node dissection (ALND) (36.6%) or no axillary surgery (16.9%). Results: Lymphatic migration was successful in 53 out of 71 patients (74.6%) and was significantly higher in patients with previous SLNB or no axillary surgery than in those with previous ALND (87.9% vs. 53.8%; p = 0.009). Aberrant lymphatic migration pathways were observed in 7 patients (13.2%). The surgical SLNB was successfully performed in 51 patients (71.8%). In 46 patients (90.2%) the SLN was histologically negative, in 3 patients (5.9%) micrometastastatic and in 2 patients (3.9%) macrometastatic. The 2 patients with a macrometastates in SLN underwent ALND, In 4 out of the 18 patients with failure of tracer migration ALND, performed as surgeon's choice, did not find any metastatic node. After a median follow-up period of 39 months (range: 2–182 months), no axillary recurrence has been diagnosed. Conclusion: A SLNB in patients with locally recurrent breast cancer, no previous ALND and negative axillary lymph nodes is technically feasible and impacts on the ALND rate. In patients who at primary surgery received ALND, migration rate is significantly lower, aberrant migration is frequent and no clinically useful information has been obtained.

AB - Objectives: To investigate the role and feasibility of sentinel lymph node biopsy (SLNB) in breast cancer patients with a local recurrence and no clinically positive axillary lymph nodes. Materials and Methods: A total of 71 patients underwent SLNB for breast cancer recurrence. At first surgery, they had received SLNB (46.5%), axillary lymph node dissection (ALND) (36.6%) or no axillary surgery (16.9%). Results: Lymphatic migration was successful in 53 out of 71 patients (74.6%) and was significantly higher in patients with previous SLNB or no axillary surgery than in those with previous ALND (87.9% vs. 53.8%; p = 0.009). Aberrant lymphatic migration pathways were observed in 7 patients (13.2%). The surgical SLNB was successfully performed in 51 patients (71.8%). In 46 patients (90.2%) the SLN was histologically negative, in 3 patients (5.9%) micrometastastatic and in 2 patients (3.9%) macrometastatic. The 2 patients with a macrometastates in SLN underwent ALND, In 4 out of the 18 patients with failure of tracer migration ALND, performed as surgeon's choice, did not find any metastatic node. After a median follow-up period of 39 months (range: 2–182 months), no axillary recurrence has been diagnosed. Conclusion: A SLNB in patients with locally recurrent breast cancer, no previous ALND and negative axillary lymph nodes is technically feasible and impacts on the ALND rate. In patients who at primary surgery received ALND, migration rate is significantly lower, aberrant migration is frequent and no clinically useful information has been obtained.

KW - Aberrant lymphatic migration

KW - Breast cancer

KW - Migration rate

KW - Outcome

KW - Recurrence

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=85049334263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049334263&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2018.06.004

DO - 10.1016/j.breast.2018.06.004

M3 - Article

C2 - 29933180

AN - SCOPUS:85049334263

VL - 41

SP - 8

EP - 13

JO - Breast

JF - Breast

SN - 0960-9776

ER -